Accolade, Inc. (NASDAQ:ACCD) Receives Average Recommendation of "Moderate Buy" from Brokerages

Accolade, Inc. (NASDAQ:ACCD) has received an average recommendation of "Moderate Buy" from brokerages. Analysts have given the stock a 12-month price target of $11.65. The company's stock has a market cap of $281.63 million and a 12-month high of $15.36. Accolade reported positive earnings for the quarter, beating estimates. Insiders have sold shares of the company, while large institutional investors have modified their holdings.

Accolade, Inc. (NASDAQ:ACCD - Get Free Report) has been given an average recommendation of "Moderate Buy" by the fifteen brokerages that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $11.65.

MarketBeat Week in Review – 7/10 - 7/14

ACCD has been the topic of several recent research reports. Wells Fargo & Company dropped their target price on Accolade from $12.00 to $10.00 and set an "equal weight" rating on the stock in a research report on Tuesday, April 30th. Truist Financial lowered their price objective on Accolade from $14.00 to $9.00 and set a "buy" rating on the stock in a research report on Friday, June 28th. Stifel Nicolaus lowered their price objective on Accolade from $13.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, June 28th. Barclays lowered their price objective on Accolade from $11.00 to $5.50 and set an "equal weight" rating on the stock in a research report on Friday, June 28th. Finally, Morgan Stanley lowered their price objective on Accolade from $12.00 to $6.00 and set an "equal weight" rating on the stock in a research report on Friday, June 28th.

View Our Latest Stock Report on Accolade

Accolade Stock Performance

Accolade: A Rising Personalized AI-Powered Healthcare Platform

ACCD stock opened at $3.52 on Friday. The firm has a market cap of $281.63 million, a PE ratio of -3.03 and a beta of 2.00. The company has a quick ratio of 2.80, a current ratio of 2.80 and a debt-to-equity ratio of 0.48. The business has a 50 day moving average of $4.77 and a 200-day moving average of $7.98. Accolade has a 12-month low of $3.35 and a 12-month high of $15.36.

Accolade (NASDAQ:ACCD - Get Free Report) last posted its quarterly earnings data on Thursday, June 27th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.13. Accolade had a negative return on equity of 20.30% and a negative net margin of 20.62%. The business had revenue of $110.50 million for the quarter, compared to the consensus estimate of $105.22 million. During the same quarter in the prior year, the business earned ($0.52) earnings per share. Accolade's revenue for the quarter was up 18.6% on a year-over-year basis. As a group, sell-side analysts expect that Accolade will post -1.17 earnings per share for the current year.

Insider Transactions at Accolade

Accolade Moves Higher But Growth Is Slowing

In other Accolade news, CAO Colin Mchugh sold 5,543 shares of Accolade stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $6.62, for a total value of $36,694.66. Following the completion of the transaction, the chief accounting officer now owns 50,177 shares of the company's stock, valued at $332,171.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders sold 19,539 shares of company stock worth $106,760. Company insiders own 8.20% of the company's stock.

Institutional Investors Weigh In On Accolade

A number of large investors have recently modified their holdings of ACCD. Swiss National Bank increased its holdings in shares of Accolade by 1.7% in the 1st quarter. Swiss National Bank now owns 137,500 shares of the company's stock valued at $1,441,000 after purchasing an additional 2,300 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Accolade by 15.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 19,540 shares of the company's stock valued at $205,000 after buying an additional 2,586 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Accolade by 22.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,373 shares of the company's stock valued at $73,000 after buying an additional 3,789 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Accolade by 39.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,584 shares of the company's stock valued at $199,000 after purchasing an additional 4,656 shares during the period. Finally, AJOVista LLC purchased a new stake in shares of Accolade during the fourth quarter valued at approximately $68,000. 84.99% of the stock is owned by hedge funds and other institutional investors.

About Accolade

(Get Free Report

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.

Should you invest $1,000 in Accolade right now?

Before you consider Accolade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Accolade wasn't on the list.

While Accolade currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here